nodes	percent_of_prediction	percent_of_DWPC	metapath
Duloxetine—CYP1A2—Anagrelide—hematologic cancer	0.0631	0.135	CbGbCtD
Duloxetine—CYP2D6—Lomustine—hematologic cancer	0.0335	0.0716	CbGbCtD
Duloxetine—CYP1A2—Carmustine—hematologic cancer	0.0331	0.0708	CbGbCtD
Duloxetine—CYP2D6—Idarubicin—hematologic cancer	0.0299	0.0638	CbGbCtD
Duloxetine—CYP1A2—Methoxsalen—hematologic cancer	0.0282	0.0602	CbGbCtD
Duloxetine—CYP1A2—Bortezomib—hematologic cancer	0.0268	0.0573	CbGbCtD
Duloxetine—CYP1A2—Daunorubicin—hematologic cancer	0.0256	0.0548	CbGbCtD
Duloxetine—CYP2D6—Hydroxyurea—hematologic cancer	0.0254	0.0542	CbGbCtD
Duloxetine—CYP1A2—Alitretinoin—hematologic cancer	0.0251	0.0537	CbGbCtD
Duloxetine—CYP1A2—Thalidomide—hematologic cancer	0.0234	0.0499	CbGbCtD
Duloxetine—CYP2D6—Bortezomib—hematologic cancer	0.0221	0.0472	CbGbCtD
Duloxetine—CYP1A2—Dacarbazine—hematologic cancer	0.0201	0.0429	CbGbCtD
Duloxetine—CYP1A2—Imatinib—hematologic cancer	0.0196	0.042	CbGbCtD
Duloxetine—CYP2D6—Imatinib—hematologic cancer	0.0162	0.0346	CbGbCtD
Duloxetine—CYP1A2—Dasatinib—hematologic cancer	0.0158	0.0337	CbGbCtD
Duloxetine—CYP2D6—Nilotinib—hematologic cancer	0.0147	0.0314	CbGbCtD
Duloxetine—CYP2D6—Vinorelbine—hematologic cancer	0.0146	0.0312	CbGbCtD
Duloxetine—CYP1A2—Etoposide—hematologic cancer	0.00983	0.021	CbGbCtD
Duloxetine—CYP2D6—Vinblastine—hematologic cancer	0.00899	0.0192	CbGbCtD
Duloxetine—CYP2D6—Dexamethasone—hematologic cancer	0.00666	0.0142	CbGbCtD
Duloxetine—CYP2D6—Doxorubicin—hematologic cancer	0.00552	0.0118	CbGbCtD
Duloxetine—NPY1R—hematopoietic system—hematologic cancer	0.00434	0.122	CbGeAlD
Duloxetine—NPY1R—gonad—hematologic cancer	0.0033	0.0926	CbGeAlD
Duloxetine—NPY1R—blood—hematologic cancer	0.00288	0.0807	CbGeAlD
Duloxetine—NPY1R—lung—hematologic cancer	0.00252	0.0708	CbGeAlD
Duloxetine—NPY1R—testis—hematologic cancer	0.00238	0.0668	CbGeAlD
Duloxetine—SLC6A3—hematopoietic system—hematologic cancer	0.00183	0.0513	CbGeAlD
Duloxetine—NPY1R—lymph node—hematologic cancer	0.00172	0.0484	CbGeAlD
Duloxetine—SLC6A4—hematopoietic system—hematologic cancer	0.00167	0.047	CbGeAlD
Duloxetine—CYP1A2—hematopoietic system—hematologic cancer	0.00113	0.0318	CbGeAlD
Duloxetine—SLC6A2—gonad—hematologic cancer	0.00112	0.0314	CbGeAlD
Duloxetine—SLC6A4—blood—hematologic cancer	0.00111	0.0311	CbGeAlD
Duloxetine—SLC6A3—lung—hematologic cancer	0.00106	0.0298	CbGeAlD
Duloxetine—SLC6A3—testis—hematologic cancer	0.001	0.0281	CbGeAlD
Duloxetine—SLC6A4—lung—hematologic cancer	0.000972	0.0273	CbGeAlD
Duloxetine—HTR2A—hematopoietic system—hematologic cancer	0.000886	0.0249	CbGeAlD
Duloxetine—SLC6A2—lung—hematologic cancer	0.000856	0.024	CbGeAlD
Duloxetine—SLC6A2—testis—hematologic cancer	0.000807	0.0227	CbGeAlD
Duloxetine—CYP2D6—hematopoietic system—hematologic cancer	0.000807	0.0226	CbGeAlD
Duloxetine—CYP1A2—blood—hematologic cancer	0.00075	0.0211	CbGeAlD
Duloxetine—HTR2A—gonad—hematologic cancer	0.000673	0.0189	CbGeAlD
Duloxetine—CYP1A2—lung—hematologic cancer	0.000658	0.0185	CbGeAlD
Duloxetine—HTR2A—blood—hematologic cancer	0.000587	0.0165	CbGeAlD
Duloxetine—SLC6A2—lymph node—hematologic cancer	0.000585	0.0164	CbGeAlD
Duloxetine—CYP2D6—blood—hematologic cancer	0.000535	0.015	CbGeAlD
Duloxetine—HTR2A—lung—hematologic cancer	0.000514	0.0144	CbGeAlD
Duloxetine—HTR2A—testis—hematologic cancer	0.000485	0.0136	CbGeAlD
Duloxetine—CYP2D6—testis—hematologic cancer	0.000442	0.0124	CbGeAlD
Duloxetine—Tinnitus—Doxorubicin—hematologic cancer	2.52e-05	6.38e-05	CcSEcCtD
Duloxetine—Anaemia—Methotrexate—hematologic cancer	2.51e-05	6.36e-05	CcSEcCtD
Duloxetine—Feeling abnormal—Dexamethasone—hematologic cancer	2.51e-05	6.35e-05	CcSEcCtD
Duloxetine—Feeling abnormal—Betamethasone—hematologic cancer	2.51e-05	6.35e-05	CcSEcCtD
Duloxetine—Flushing—Doxorubicin—hematologic cancer	2.51e-05	6.35e-05	CcSEcCtD
Duloxetine—Cardiac disorder—Doxorubicin—hematologic cancer	2.51e-05	6.35e-05	CcSEcCtD
Duloxetine—Flatulence—Epirubicin—hematologic cancer	2.5e-05	6.34e-05	CcSEcCtD
Duloxetine—Tension—Epirubicin—hematologic cancer	2.49e-05	6.32e-05	CcSEcCtD
Duloxetine—Gastrointestinal pain—Betamethasone—hematologic cancer	2.49e-05	6.31e-05	CcSEcCtD
Duloxetine—Gastrointestinal pain—Dexamethasone—hematologic cancer	2.49e-05	6.31e-05	CcSEcCtD
Duloxetine—Dysgeusia—Epirubicin—hematologic cancer	2.49e-05	6.3e-05	CcSEcCtD
Duloxetine—Hypersensitivity—Triamcinolone—hematologic cancer	2.47e-05	6.26e-05	CcSEcCtD
Duloxetine—Nervousness—Epirubicin—hematologic cancer	2.47e-05	6.25e-05	CcSEcCtD
Duloxetine—Back pain—Epirubicin—hematologic cancer	2.46e-05	6.23e-05	CcSEcCtD
Duloxetine—Angiopathy—Doxorubicin—hematologic cancer	2.45e-05	6.21e-05	CcSEcCtD
Duloxetine—Malaise—Methotrexate—hematologic cancer	2.45e-05	6.2e-05	CcSEcCtD
Duloxetine—Dizziness—Etoposide—hematologic cancer	2.45e-05	6.2e-05	CcSEcCtD
Duloxetine—Muscle spasms—Epirubicin—hematologic cancer	2.44e-05	6.19e-05	CcSEcCtD
Duloxetine—Immune system disorder—Doxorubicin—hematologic cancer	2.44e-05	6.18e-05	CcSEcCtD
Duloxetine—Vertigo—Methotrexate—hematologic cancer	2.44e-05	6.18e-05	CcSEcCtD
Duloxetine—Mediastinal disorder—Doxorubicin—hematologic cancer	2.43e-05	6.17e-05	CcSEcCtD
Duloxetine—Leukopenia—Methotrexate—hematologic cancer	2.43e-05	6.16e-05	CcSEcCtD
Duloxetine—Chills—Doxorubicin—hematologic cancer	2.42e-05	6.14e-05	CcSEcCtD
Duloxetine—Urticaria—Betamethasone—hematologic cancer	2.42e-05	6.13e-05	CcSEcCtD
Duloxetine—Urticaria—Dexamethasone—hematologic cancer	2.42e-05	6.13e-05	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Prednisone—hematologic cancer	2.42e-05	6.12e-05	CcSEcCtD
Duloxetine—Dizziness—Prednisolone—hematologic cancer	2.41e-05	6.11e-05	CcSEcCtD
Duloxetine—Arrhythmia—Doxorubicin—hematologic cancer	2.41e-05	6.11e-05	CcSEcCtD
Duloxetine—Asthenia—Triamcinolone—hematologic cancer	2.41e-05	6.1e-05	CcSEcCtD
Duloxetine—Body temperature increased—Betamethasone—hematologic cancer	2.41e-05	6.1e-05	CcSEcCtD
Duloxetine—Abdominal pain—Dexamethasone—hematologic cancer	2.41e-05	6.1e-05	CcSEcCtD
Duloxetine—Abdominal pain—Betamethasone—hematologic cancer	2.41e-05	6.1e-05	CcSEcCtD
Duloxetine—Body temperature increased—Dexamethasone—hematologic cancer	2.41e-05	6.1e-05	CcSEcCtD
Duloxetine—Nausea—Cisplatin—hematologic cancer	2.4e-05	6.08e-05	CcSEcCtD
Duloxetine—Insomnia—Prednisone—hematologic cancer	2.4e-05	6.07e-05	CcSEcCtD
Duloxetine—Vision blurred—Epirubicin—hematologic cancer	2.4e-05	6.07e-05	CcSEcCtD
Duloxetine—Alopecia—Doxorubicin—hematologic cancer	2.39e-05	6.04e-05	CcSEcCtD
Duloxetine—Paraesthesia—Prednisone—hematologic cancer	2.38e-05	6.03e-05	CcSEcCtD
Duloxetine—Pruritus—Triamcinolone—hematologic cancer	2.37e-05	6.01e-05	CcSEcCtD
Duloxetine—Cough—Methotrexate—hematologic cancer	2.37e-05	6e-05	CcSEcCtD
Duloxetine—Mental disorder—Doxorubicin—hematologic cancer	2.37e-05	5.99e-05	CcSEcCtD
Duloxetine—Ill-defined disorder—Epirubicin—hematologic cancer	2.36e-05	5.97e-05	CcSEcCtD
Duloxetine—Convulsion—Methotrexate—hematologic cancer	2.35e-05	5.96e-05	CcSEcCtD
Duloxetine—Vomiting—Etoposide—hematologic cancer	2.35e-05	5.96e-05	CcSEcCtD
Duloxetine—Erythema—Doxorubicin—hematologic cancer	2.35e-05	5.95e-05	CcSEcCtD
Duloxetine—Malnutrition—Doxorubicin—hematologic cancer	2.35e-05	5.95e-05	CcSEcCtD
Duloxetine—Anaemia—Epirubicin—hematologic cancer	2.35e-05	5.95e-05	CcSEcCtD
Duloxetine—Agitation—Epirubicin—hematologic cancer	2.34e-05	5.91e-05	CcSEcCtD
Duloxetine—Dyspepsia—Prednisone—hematologic cancer	2.33e-05	5.91e-05	CcSEcCtD
Duloxetine—Rash—Etoposide—hematologic cancer	2.33e-05	5.91e-05	CcSEcCtD
Duloxetine—Dermatitis—Etoposide—hematologic cancer	2.33e-05	5.9e-05	CcSEcCtD
Duloxetine—Headache—Etoposide—hematologic cancer	2.32e-05	5.87e-05	CcSEcCtD
Duloxetine—Flatulence—Doxorubicin—hematologic cancer	2.32e-05	5.87e-05	CcSEcCtD
Duloxetine—Arthralgia—Methotrexate—hematologic cancer	2.31e-05	5.85e-05	CcSEcCtD
Duloxetine—Myalgia—Methotrexate—hematologic cancer	2.31e-05	5.85e-05	CcSEcCtD
Duloxetine—Chest pain—Methotrexate—hematologic cancer	2.31e-05	5.85e-05	CcSEcCtD
Duloxetine—Tension—Doxorubicin—hematologic cancer	2.31e-05	5.84e-05	CcSEcCtD
Duloxetine—Decreased appetite—Prednisone—hematologic cancer	2.31e-05	5.84e-05	CcSEcCtD
Duloxetine—Dysgeusia—Doxorubicin—hematologic cancer	2.3e-05	5.83e-05	CcSEcCtD
Duloxetine—Rash—Prednisolone—hematologic cancer	2.3e-05	5.83e-05	CcSEcCtD
Duloxetine—Dermatitis—Prednisolone—hematologic cancer	2.3e-05	5.82e-05	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	2.3e-05	5.81e-05	CcSEcCtD
Duloxetine—Malaise—Epirubicin—hematologic cancer	2.29e-05	5.8e-05	CcSEcCtD
Duloxetine—Fatigue—Prednisone—hematologic cancer	2.29e-05	5.79e-05	CcSEcCtD
Duloxetine—Headache—Prednisolone—hematologic cancer	2.29e-05	5.79e-05	CcSEcCtD
Duloxetine—Discomfort—Methotrexate—hematologic cancer	2.28e-05	5.78e-05	CcSEcCtD
Duloxetine—Nervousness—Doxorubicin—hematologic cancer	2.28e-05	5.78e-05	CcSEcCtD
Duloxetine—Vertigo—Epirubicin—hematologic cancer	2.28e-05	5.78e-05	CcSEcCtD
Duloxetine—Syncope—Epirubicin—hematologic cancer	2.28e-05	5.77e-05	CcSEcCtD
Duloxetine—Leukopenia—Epirubicin—hematologic cancer	2.28e-05	5.76e-05	CcSEcCtD
Duloxetine—Back pain—Doxorubicin—hematologic cancer	2.27e-05	5.76e-05	CcSEcCtD
Duloxetine—Constipation—Prednisone—hematologic cancer	2.27e-05	5.74e-05	CcSEcCtD
Duloxetine—Muscle spasms—Doxorubicin—hematologic cancer	2.26e-05	5.73e-05	CcSEcCtD
Duloxetine—Palpitations—Epirubicin—hematologic cancer	2.25e-05	5.69e-05	CcSEcCtD
Duloxetine—Confusional state—Methotrexate—hematologic cancer	2.24e-05	5.66e-05	CcSEcCtD
Duloxetine—Loss of consciousness—Epirubicin—hematologic cancer	2.23e-05	5.66e-05	CcSEcCtD
Duloxetine—Dizziness—Triamcinolone—hematologic cancer	2.22e-05	5.62e-05	CcSEcCtD
Duloxetine—Cough—Epirubicin—hematologic cancer	2.22e-05	5.62e-05	CcSEcCtD
Duloxetine—Anaphylactic shock—Methotrexate—hematologic cancer	2.22e-05	5.61e-05	CcSEcCtD
Duloxetine—Vision blurred—Doxorubicin—hematologic cancer	2.22e-05	5.61e-05	CcSEcCtD
Duloxetine—Convulsion—Epirubicin—hematologic cancer	2.2e-05	5.58e-05	CcSEcCtD
Duloxetine—Infection—Methotrexate—hematologic cancer	2.2e-05	5.58e-05	CcSEcCtD
Duloxetine—Nausea—Etoposide—hematologic cancer	2.2e-05	5.57e-05	CcSEcCtD
Duloxetine—Hypertension—Epirubicin—hematologic cancer	2.19e-05	5.56e-05	CcSEcCtD
Duloxetine—Feeling abnormal—Prednisone—hematologic cancer	2.19e-05	5.53e-05	CcSEcCtD
Duloxetine—Asthenia—Dexamethasone—hematologic cancer	2.19e-05	5.53e-05	CcSEcCtD
Duloxetine—Asthenia—Betamethasone—hematologic cancer	2.19e-05	5.53e-05	CcSEcCtD
Duloxetine—Ill-defined disorder—Doxorubicin—hematologic cancer	2.18e-05	5.53e-05	CcSEcCtD
Duloxetine—Nervous system disorder—Methotrexate—hematologic cancer	2.17e-05	5.5e-05	CcSEcCtD
Duloxetine—Anaemia—Doxorubicin—hematologic cancer	2.17e-05	5.5e-05	CcSEcCtD
Duloxetine—Thrombocytopenia—Methotrexate—hematologic cancer	2.17e-05	5.5e-05	CcSEcCtD
Duloxetine—Gastrointestinal pain—Prednisone—hematologic cancer	2.17e-05	5.49e-05	CcSEcCtD
Duloxetine—Nausea—Prednisolone—hematologic cancer	2.17e-05	5.49e-05	CcSEcCtD
Duloxetine—Myalgia—Epirubicin—hematologic cancer	2.16e-05	5.48e-05	CcSEcCtD
Duloxetine—Chest pain—Epirubicin—hematologic cancer	2.16e-05	5.48e-05	CcSEcCtD
Duloxetine—Arthralgia—Epirubicin—hematologic cancer	2.16e-05	5.48e-05	CcSEcCtD
Duloxetine—Agitation—Doxorubicin—hematologic cancer	2.16e-05	5.47e-05	CcSEcCtD
Duloxetine—Anxiety—Epirubicin—hematologic cancer	2.16e-05	5.46e-05	CcSEcCtD
Duloxetine—Pruritus—Dexamethasone—hematologic cancer	2.15e-05	5.46e-05	CcSEcCtD
Duloxetine—Pruritus—Betamethasone—hematologic cancer	2.15e-05	5.46e-05	CcSEcCtD
Duloxetine—Skin disorder—Methotrexate—hematologic cancer	2.15e-05	5.45e-05	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	2.15e-05	5.44e-05	CcSEcCtD
Duloxetine—Hyperhidrosis—Methotrexate—hematologic cancer	2.14e-05	5.43e-05	CcSEcCtD
Duloxetine—Discomfort—Epirubicin—hematologic cancer	2.14e-05	5.41e-05	CcSEcCtD
Duloxetine—Vomiting—Triamcinolone—hematologic cancer	2.13e-05	5.4e-05	CcSEcCtD
Duloxetine—Malaise—Doxorubicin—hematologic cancer	2.12e-05	5.37e-05	CcSEcCtD
Duloxetine—Rash—Triamcinolone—hematologic cancer	2.12e-05	5.36e-05	CcSEcCtD
Duloxetine—Dry mouth—Epirubicin—hematologic cancer	2.12e-05	5.36e-05	CcSEcCtD
Duloxetine—Dermatitis—Triamcinolone—hematologic cancer	2.11e-05	5.35e-05	CcSEcCtD
Duloxetine—Vertigo—Doxorubicin—hematologic cancer	2.11e-05	5.35e-05	CcSEcCtD
Duloxetine—Anorexia—Methotrexate—hematologic cancer	2.11e-05	5.35e-05	CcSEcCtD
Duloxetine—Syncope—Doxorubicin—hematologic cancer	2.11e-05	5.34e-05	CcSEcCtD
Duloxetine—Urticaria—Prednisone—hematologic cancer	2.11e-05	5.34e-05	CcSEcCtD
Duloxetine—Leukopenia—Doxorubicin—hematologic cancer	2.11e-05	5.33e-05	CcSEcCtD
Duloxetine—Headache—Triamcinolone—hematologic cancer	2.1e-05	5.32e-05	CcSEcCtD
Duloxetine—Abdominal pain—Prednisone—hematologic cancer	2.1e-05	5.31e-05	CcSEcCtD
Duloxetine—Body temperature increased—Prednisone—hematologic cancer	2.1e-05	5.31e-05	CcSEcCtD
Duloxetine—Confusional state—Epirubicin—hematologic cancer	2.09e-05	5.3e-05	CcSEcCtD
Duloxetine—Diarrhoea—Dexamethasone—hematologic cancer	2.08e-05	5.28e-05	CcSEcCtD
Duloxetine—Diarrhoea—Betamethasone—hematologic cancer	2.08e-05	5.28e-05	CcSEcCtD
Duloxetine—Palpitations—Doxorubicin—hematologic cancer	2.08e-05	5.26e-05	CcSEcCtD
Duloxetine—Anaphylactic shock—Epirubicin—hematologic cancer	2.07e-05	5.25e-05	CcSEcCtD
Duloxetine—Oedema—Epirubicin—hematologic cancer	2.07e-05	5.25e-05	CcSEcCtD
Duloxetine—Loss of consciousness—Doxorubicin—hematologic cancer	2.07e-05	5.23e-05	CcSEcCtD
Duloxetine—Infection—Epirubicin—hematologic cancer	2.06e-05	5.22e-05	CcSEcCtD
Duloxetine—Cough—Doxorubicin—hematologic cancer	2.05e-05	5.2e-05	CcSEcCtD
Duloxetine—Shock—Epirubicin—hematologic cancer	2.04e-05	5.17e-05	CcSEcCtD
Duloxetine—Convulsion—Doxorubicin—hematologic cancer	2.04e-05	5.16e-05	CcSEcCtD
Duloxetine—Nervous system disorder—Epirubicin—hematologic cancer	2.03e-05	5.15e-05	CcSEcCtD
Duloxetine—Thrombocytopenia—Epirubicin—hematologic cancer	2.03e-05	5.14e-05	CcSEcCtD
Duloxetine—Hypertension—Doxorubicin—hematologic cancer	2.03e-05	5.14e-05	CcSEcCtD
Duloxetine—Tachycardia—Epirubicin—hematologic cancer	2.02e-05	5.13e-05	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Methotrexate—hematologic cancer	2.02e-05	5.11e-05	CcSEcCtD
Duloxetine—Skin disorder—Epirubicin—hematologic cancer	2.01e-05	5.1e-05	CcSEcCtD
Duloxetine—Dizziness—Betamethasone—hematologic cancer	2.01e-05	5.1e-05	CcSEcCtD
Duloxetine—Dizziness—Dexamethasone—hematologic cancer	2.01e-05	5.1e-05	CcSEcCtD
Duloxetine—Hyperhidrosis—Epirubicin—hematologic cancer	2.01e-05	5.08e-05	CcSEcCtD
Duloxetine—Insomnia—Methotrexate—hematologic cancer	2e-05	5.08e-05	CcSEcCtD
Duloxetine—Chest pain—Doxorubicin—hematologic cancer	2e-05	5.07e-05	CcSEcCtD
Duloxetine—Arthralgia—Doxorubicin—hematologic cancer	2e-05	5.07e-05	CcSEcCtD
Duloxetine—Myalgia—Doxorubicin—hematologic cancer	2e-05	5.07e-05	CcSEcCtD
Duloxetine—Anxiety—Doxorubicin—hematologic cancer	2e-05	5.05e-05	CcSEcCtD
Duloxetine—Nausea—Triamcinolone—hematologic cancer	1.99e-05	5.05e-05	CcSEcCtD
Duloxetine—Paraesthesia—Methotrexate—hematologic cancer	1.99e-05	5.04e-05	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	1.99e-05	5.03e-05	CcSEcCtD
Duloxetine—Discomfort—Doxorubicin—hematologic cancer	1.98e-05	5.01e-05	CcSEcCtD
Duloxetine—Anorexia—Epirubicin—hematologic cancer	1.98e-05	5.01e-05	CcSEcCtD
Duloxetine—Somnolence—Methotrexate—hematologic cancer	1.97e-05	4.99e-05	CcSEcCtD
Duloxetine—Dry mouth—Doxorubicin—hematologic cancer	1.96e-05	4.96e-05	CcSEcCtD
Duloxetine—Hypersensitivity—Prednisone—hematologic cancer	1.95e-05	4.95e-05	CcSEcCtD
Duloxetine—Dyspepsia—Methotrexate—hematologic cancer	1.95e-05	4.94e-05	CcSEcCtD
Duloxetine—Vomiting—Betamethasone—hematologic cancer	1.94e-05	4.9e-05	CcSEcCtD
Duloxetine—Vomiting—Dexamethasone—hematologic cancer	1.94e-05	4.9e-05	CcSEcCtD
Duloxetine—Confusional state—Doxorubicin—hematologic cancer	1.94e-05	4.9e-05	CcSEcCtD
Duloxetine—Decreased appetite—Methotrexate—hematologic cancer	1.93e-05	4.88e-05	CcSEcCtD
Duloxetine—Rash—Dexamethasone—hematologic cancer	1.92e-05	4.86e-05	CcSEcCtD
Duloxetine—Rash—Betamethasone—hematologic cancer	1.92e-05	4.86e-05	CcSEcCtD
Duloxetine—Anaphylactic shock—Doxorubicin—hematologic cancer	1.92e-05	4.86e-05	CcSEcCtD
Duloxetine—Oedema—Doxorubicin—hematologic cancer	1.92e-05	4.86e-05	CcSEcCtD
Duloxetine—Dermatitis—Dexamethasone—hematologic cancer	1.92e-05	4.86e-05	CcSEcCtD
Duloxetine—Dermatitis—Betamethasone—hematologic cancer	1.92e-05	4.86e-05	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Methotrexate—hematologic cancer	1.91e-05	4.85e-05	CcSEcCtD
Duloxetine—Fatigue—Methotrexate—hematologic cancer	1.91e-05	4.84e-05	CcSEcCtD
Duloxetine—Headache—Dexamethasone—hematologic cancer	1.91e-05	4.83e-05	CcSEcCtD
Duloxetine—Headache—Betamethasone—hematologic cancer	1.91e-05	4.83e-05	CcSEcCtD
Duloxetine—Infection—Doxorubicin—hematologic cancer	1.91e-05	4.83e-05	CcSEcCtD
Duloxetine—Asthenia—Prednisone—hematologic cancer	1.9e-05	4.82e-05	CcSEcCtD
Duloxetine—Pain—Methotrexate—hematologic cancer	1.9e-05	4.8e-05	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Epirubicin—hematologic cancer	1.89e-05	4.79e-05	CcSEcCtD
Duloxetine—Shock—Doxorubicin—hematologic cancer	1.89e-05	4.78e-05	CcSEcCtD
Duloxetine—Nervous system disorder—Doxorubicin—hematologic cancer	1.88e-05	4.77e-05	CcSEcCtD
Duloxetine—Thrombocytopenia—Doxorubicin—hematologic cancer	1.88e-05	4.76e-05	CcSEcCtD
Duloxetine—Pruritus—Prednisone—hematologic cancer	1.88e-05	4.75e-05	CcSEcCtD
Duloxetine—Insomnia—Epirubicin—hematologic cancer	1.88e-05	4.75e-05	CcSEcCtD
Duloxetine—Tachycardia—Doxorubicin—hematologic cancer	1.87e-05	4.74e-05	CcSEcCtD
Duloxetine—Skin disorder—Doxorubicin—hematologic cancer	1.86e-05	4.72e-05	CcSEcCtD
Duloxetine—Paraesthesia—Epirubicin—hematologic cancer	1.86e-05	4.72e-05	CcSEcCtD
Duloxetine—Hyperhidrosis—Doxorubicin—hematologic cancer	1.86e-05	4.7e-05	CcSEcCtD
Duloxetine—Somnolence—Epirubicin—hematologic cancer	1.84e-05	4.67e-05	CcSEcCtD
Duloxetine—Anorexia—Doxorubicin—hematologic cancer	1.83e-05	4.63e-05	CcSEcCtD
Duloxetine—Feeling abnormal—Methotrexate—hematologic cancer	1.83e-05	4.63e-05	CcSEcCtD
Duloxetine—Dyspepsia—Epirubicin—hematologic cancer	1.83e-05	4.62e-05	CcSEcCtD
Duloxetine—Diarrhoea—Prednisone—hematologic cancer	1.81e-05	4.6e-05	CcSEcCtD
Duloxetine—Gastrointestinal pain—Methotrexate—hematologic cancer	1.81e-05	4.59e-05	CcSEcCtD
Duloxetine—Nausea—Betamethasone—hematologic cancer	1.81e-05	4.58e-05	CcSEcCtD
Duloxetine—Nausea—Dexamethasone—hematologic cancer	1.81e-05	4.58e-05	CcSEcCtD
Duloxetine—Decreased appetite—Epirubicin—hematologic cancer	1.8e-05	4.57e-05	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Epirubicin—hematologic cancer	1.79e-05	4.53e-05	CcSEcCtD
Duloxetine—Fatigue—Epirubicin—hematologic cancer	1.79e-05	4.53e-05	CcSEcCtD
Duloxetine—Constipation—Epirubicin—hematologic cancer	1.77e-05	4.49e-05	CcSEcCtD
Duloxetine—Pain—Epirubicin—hematologic cancer	1.77e-05	4.49e-05	CcSEcCtD
Duloxetine—Urticaria—Methotrexate—hematologic cancer	1.76e-05	4.46e-05	CcSEcCtD
Duloxetine—Dizziness—Prednisone—hematologic cancer	1.75e-05	4.44e-05	CcSEcCtD
Duloxetine—Abdominal pain—Methotrexate—hematologic cancer	1.75e-05	4.44e-05	CcSEcCtD
Duloxetine—Body temperature increased—Methotrexate—hematologic cancer	1.75e-05	4.44e-05	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	1.75e-05	4.43e-05	CcSEcCtD
Duloxetine—Insomnia—Doxorubicin—hematologic cancer	1.74e-05	4.4e-05	CcSEcCtD
Duloxetine—Paraesthesia—Doxorubicin—hematologic cancer	1.72e-05	4.36e-05	CcSEcCtD
Duloxetine—Feeling abnormal—Epirubicin—hematologic cancer	1.71e-05	4.33e-05	CcSEcCtD
Duloxetine—Somnolence—Doxorubicin—hematologic cancer	1.71e-05	4.32e-05	CcSEcCtD
Duloxetine—Gastrointestinal pain—Epirubicin—hematologic cancer	1.7e-05	4.3e-05	CcSEcCtD
Duloxetine—Dyspepsia—Doxorubicin—hematologic cancer	1.69e-05	4.28e-05	CcSEcCtD
Duloxetine—Vomiting—Prednisone—hematologic cancer	1.69e-05	4.27e-05	CcSEcCtD
Duloxetine—Rash—Prednisone—hematologic cancer	1.67e-05	4.23e-05	CcSEcCtD
Duloxetine—Dermatitis—Prednisone—hematologic cancer	1.67e-05	4.23e-05	CcSEcCtD
Duloxetine—Decreased appetite—Doxorubicin—hematologic cancer	1.67e-05	4.22e-05	CcSEcCtD
Duloxetine—Headache—Prednisone—hematologic cancer	1.66e-05	4.21e-05	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Doxorubicin—hematologic cancer	1.66e-05	4.2e-05	CcSEcCtD
Duloxetine—Fatigue—Doxorubicin—hematologic cancer	1.65e-05	4.19e-05	CcSEcCtD
Duloxetine—Urticaria—Epirubicin—hematologic cancer	1.65e-05	4.17e-05	CcSEcCtD
Duloxetine—Constipation—Doxorubicin—hematologic cancer	1.64e-05	4.16e-05	CcSEcCtD
Duloxetine—Pain—Doxorubicin—hematologic cancer	1.64e-05	4.16e-05	CcSEcCtD
Duloxetine—Abdominal pain—Epirubicin—hematologic cancer	1.64e-05	4.15e-05	CcSEcCtD
Duloxetine—Body temperature increased—Epirubicin—hematologic cancer	1.64e-05	4.15e-05	CcSEcCtD
Duloxetine—Hypersensitivity—Methotrexate—hematologic cancer	1.63e-05	4.14e-05	CcSEcCtD
Duloxetine—Asthenia—Methotrexate—hematologic cancer	1.59e-05	4.03e-05	CcSEcCtD
Duloxetine—Feeling abnormal—Doxorubicin—hematologic cancer	1.58e-05	4e-05	CcSEcCtD
Duloxetine—Nausea—Prednisone—hematologic cancer	1.58e-05	3.99e-05	CcSEcCtD
Duloxetine—Gastrointestinal pain—Doxorubicin—hematologic cancer	1.57e-05	3.97e-05	CcSEcCtD
Duloxetine—Pruritus—Methotrexate—hematologic cancer	1.57e-05	3.97e-05	CcSEcCtD
Duloxetine—Hypersensitivity—Epirubicin—hematologic cancer	1.53e-05	3.87e-05	CcSEcCtD
Duloxetine—Urticaria—Doxorubicin—hematologic cancer	1.52e-05	3.86e-05	CcSEcCtD
Duloxetine—Body temperature increased—Doxorubicin—hematologic cancer	1.52e-05	3.84e-05	CcSEcCtD
Duloxetine—Abdominal pain—Doxorubicin—hematologic cancer	1.52e-05	3.84e-05	CcSEcCtD
Duloxetine—Diarrhoea—Methotrexate—hematologic cancer	1.52e-05	3.84e-05	CcSEcCtD
Duloxetine—Asthenia—Epirubicin—hematologic cancer	1.49e-05	3.77e-05	CcSEcCtD
Duloxetine—Pruritus—Epirubicin—hematologic cancer	1.47e-05	3.72e-05	CcSEcCtD
Duloxetine—Dizziness—Methotrexate—hematologic cancer	1.47e-05	3.71e-05	CcSEcCtD
Duloxetine—Diarrhoea—Epirubicin—hematologic cancer	1.42e-05	3.59e-05	CcSEcCtD
Duloxetine—Hypersensitivity—Doxorubicin—hematologic cancer	1.41e-05	3.58e-05	CcSEcCtD
Duloxetine—Vomiting—Methotrexate—hematologic cancer	1.41e-05	3.57e-05	CcSEcCtD
Duloxetine—Rash—Methotrexate—hematologic cancer	1.4e-05	3.54e-05	CcSEcCtD
Duloxetine—Dermatitis—Methotrexate—hematologic cancer	1.4e-05	3.54e-05	CcSEcCtD
Duloxetine—Headache—Methotrexate—hematologic cancer	1.39e-05	3.52e-05	CcSEcCtD
Duloxetine—Asthenia—Doxorubicin—hematologic cancer	1.38e-05	3.49e-05	CcSEcCtD
Duloxetine—Dizziness—Epirubicin—hematologic cancer	1.37e-05	3.47e-05	CcSEcCtD
Duloxetine—Pruritus—Doxorubicin—hematologic cancer	1.36e-05	3.44e-05	CcSEcCtD
Duloxetine—Vomiting—Epirubicin—hematologic cancer	1.32e-05	3.34e-05	CcSEcCtD
Duloxetine—Nausea—Methotrexate—hematologic cancer	1.32e-05	3.33e-05	CcSEcCtD
Duloxetine—Diarrhoea—Doxorubicin—hematologic cancer	1.31e-05	3.33e-05	CcSEcCtD
Duloxetine—Rash—Epirubicin—hematologic cancer	1.31e-05	3.31e-05	CcSEcCtD
Duloxetine—Dermatitis—Epirubicin—hematologic cancer	1.31e-05	3.31e-05	CcSEcCtD
Duloxetine—Headache—Epirubicin—hematologic cancer	1.3e-05	3.29e-05	CcSEcCtD
Duloxetine—Dizziness—Doxorubicin—hematologic cancer	1.27e-05	3.21e-05	CcSEcCtD
Duloxetine—Nausea—Epirubicin—hematologic cancer	1.23e-05	3.12e-05	CcSEcCtD
Duloxetine—Vomiting—Doxorubicin—hematologic cancer	1.22e-05	3.09e-05	CcSEcCtD
Duloxetine—Rash—Doxorubicin—hematologic cancer	1.21e-05	3.06e-05	CcSEcCtD
Duloxetine—Dermatitis—Doxorubicin—hematologic cancer	1.21e-05	3.06e-05	CcSEcCtD
Duloxetine—Headache—Doxorubicin—hematologic cancer	1.2e-05	3.04e-05	CcSEcCtD
Duloxetine—Nausea—Doxorubicin—hematologic cancer	1.14e-05	2.89e-05	CcSEcCtD
Duloxetine—CYP2D6—Metabolism—GSTT1—hematologic cancer	8.16e-06	8.05e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—MAP2K1—hematologic cancer	8.15e-06	8.05e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—SLC22A1—hematologic cancer	8.15e-06	8.05e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CRABP1—hematologic cancer	8.15e-06	8.05e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—MAPK3—hematologic cancer	8.15e-06	8.04e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—PIK3CB—hematologic cancer	8.13e-06	8.02e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—GRB2—hematologic cancer	8.11e-06	8.01e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CREB1—hematologic cancer	8.1e-06	7.99e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—PIK3CD—hematologic cancer	8.1e-06	7.99e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PDGFA—hematologic cancer	8.09e-06	7.99e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PDGFRA—hematologic cancer	8.08e-06	7.98e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—JAK1—hematologic cancer	8.05e-06	7.95e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PRKCG—hematologic cancer	8.05e-06	7.95e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—BRAF—hematologic cancer	8e-06	7.89e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—KITLG—hematologic cancer	7.97e-06	7.87e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—SDC1—hematologic cancer	7.97e-06	7.87e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ALOX5—hematologic cancer	7.94e-06	7.84e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CCL2—hematologic cancer	7.93e-06	7.82e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IL6R—hematologic cancer	7.9e-06	7.8e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CREBBP—hematologic cancer	7.89e-06	7.79e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—STAT5A—hematologic cancer	7.79e-06	7.69e-05	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—PIK3CB—hematologic cancer	7.77e-06	7.67e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CDKN2B—hematologic cancer	7.73e-06	7.63e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—NUP98—hematologic cancer	7.69e-06	7.59e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—PIK3R1—hematologic cancer	7.65e-06	7.55e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MAP2K1—hematologic cancer	7.53e-06	7.43e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IL2RA—hematologic cancer	7.52e-06	7.42e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PIK3CD—hematologic cancer	7.48e-06	7.38e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CD86—hematologic cancer	7.47e-06	7.38e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ADCY7—hematologic cancer	7.47e-06	7.37e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—NCOA3—hematologic cancer	7.47e-06	7.37e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—IL2—hematologic cancer	7.46e-06	7.37e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TERT—hematologic cancer	7.44e-06	7.34e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—JAK2—hematologic cancer	7.43e-06	7.34e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—NUP214—hematologic cancer	7.42e-06	7.32e-05	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—PIK3CA—hematologic cancer	7.41e-06	7.31e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—HES1—hematologic cancer	7.37e-06	7.28e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	7.34e-06	7.24e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NCOR1—hematologic cancer	7.33e-06	7.23e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—KRAS—hematologic cancer	7.32e-06	7.23e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—MTR—hematologic cancer	7.26e-06	7.17e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ABCG2—hematologic cancer	7.26e-06	7.17e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PDGFB—hematologic cancer	7.26e-06	7.17e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—FGF1—hematologic cancer	7.25e-06	7.15e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CSF2—hematologic cancer	7.25e-06	7.15e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—FGF2—hematologic cancer	7.16e-06	7.07e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—FOXO1—hematologic cancer	7.14e-06	7.05e-05	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—IL2—hematologic cancer	7.14e-06	7.05e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PDGFRB—hematologic cancer	7.13e-06	7.04e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ENO2—hematologic cancer	7.12e-06	7.03e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TSC2—hematologic cancer	7.1e-06	7e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PIK3R1—hematologic cancer	7.06e-06	6.97e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—PIK3CB—hematologic cancer	7.06e-06	6.97e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PDGFRA—hematologic cancer	7.02e-06	6.93e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PRKCG—hematologic cancer	6.99e-06	6.9e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—JAK1—hematologic cancer	6.99e-06	6.9e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GSTT1—hematologic cancer	6.91e-06	6.82e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—JAK2—hematologic cancer	6.87e-06	6.78e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—FGFR3—hematologic cancer	6.83e-06	6.74e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	6.8e-06	6.72e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CD44—hematologic cancer	6.78e-06	6.69e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—NQO1—hematologic cancer	6.78e-06	6.69e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MAPK14—hematologic cancer	6.76e-06	6.67e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—SDC1—hematologic cancer	6.75e-06	6.67e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—PIK3CA—hematologic cancer	6.73e-06	6.64e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MDM2—hematologic cancer	6.7e-06	6.61e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—ESR1—hematologic cancer	6.63e-06	6.54e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—FN1—hematologic cancer	6.55e-06	6.46e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IL2RA—hematologic cancer	6.53e-06	6.45e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MTOR—hematologic cancer	6.52e-06	6.44e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PIK3CB—hematologic cancer	6.52e-06	6.44e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—IL2—hematologic cancer	6.48e-06	6.4e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—BAD—hematologic cancer	6.47e-06	6.39e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NFKBIA—hematologic cancer	6.47e-06	6.39e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TERT—hematologic cancer	6.46e-06	6.38e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	6.45e-06	6.37e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CYCS—hematologic cancer	6.41e-06	6.33e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NOTCH1—hematologic cancer	6.41e-06	6.32e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—HSP90AA1—hematologic cancer	6.37e-06	6.29e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	6.37e-06	6.29e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PDGFB—hematologic cancer	6.3e-06	6.22e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CD80—hematologic cancer	6.28e-06	6.2e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PIK3CG—hematologic cancer	6.27e-06	6.19e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—KIT—hematologic cancer	6.27e-06	6.19e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—NRAS—hematologic cancer	6.27e-06	6.19e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—HRAS—hematologic cancer	6.23e-06	6.14e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TSC2—hematologic cancer	6.16e-06	6.08e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PTPN11—hematologic cancer	6.16e-06	6.08e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CDKN1B—hematologic cancer	6.12e-06	6.04e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	6.09e-06	6.01e-05	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—AKT1—hematologic cancer	6.05e-06	5.97e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—MAPK3—hematologic cancer	6e-06	5.92e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CASP3—hematologic cancer	6e-06	5.92e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IL2—hematologic cancer	5.99e-06	5.91e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CREB1—hematologic cancer	5.96e-06	5.89e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—IL6—hematologic cancer	5.96e-06	5.88e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—FGFR3—hematologic cancer	5.93e-06	5.85e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—BRAF—hematologic cancer	5.89e-06	5.81e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MAPK14—hematologic cancer	5.87e-06	5.79e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CCND1—hematologic cancer	5.84e-06	5.76e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CCL2—hematologic cancer	5.84e-06	5.76e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—JUN—hematologic cancer	5.83e-06	5.75e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IL6R—hematologic cancer	5.82e-06	5.74e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CREBBP—hematologic cancer	5.81e-06	5.73e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—ESR1—hematologic cancer	5.76e-06	5.68e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CD44—hematologic cancer	5.74e-06	5.67e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—NQO1—hematologic cancer	5.74e-06	5.67e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—FN1—hematologic cancer	5.69e-06	5.61e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GSTP1—hematologic cancer	5.65e-06	5.58e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CDKN1A—hematologic cancer	5.65e-06	5.57e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PTEN—hematologic cancer	5.63e-06	5.56e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	5.62e-06	5.55e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—BAD—hematologic cancer	5.62e-06	5.55e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NFKBIA—hematologic cancer	5.62e-06	5.55e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NOTCH1—hematologic cancer	5.56e-06	5.49e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MAP2K1—hematologic cancer	5.55e-06	5.47e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MAPK8—hematologic cancer	5.51e-06	5.44e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PIK3CD—hematologic cancer	5.51e-06	5.44e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—AKT1—hematologic cancer	5.5e-06	5.43e-05	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—PIK3CA—hematologic cancer	5.46e-06	5.39e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CD80—hematologic cancer	5.45e-06	5.38e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PIK3CG—hematologic cancer	5.44e-06	5.37e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—KIT—hematologic cancer	5.44e-06	5.37e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—NRAS—hematologic cancer	5.44e-06	5.37e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CYCS—hematologic cancer	5.43e-06	5.36e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—HSP90AA1—hematologic cancer	5.4e-06	5.33e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—KRAS—hematologic cancer	5.39e-06	5.32e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—EP300—hematologic cancer	5.37e-06	5.3e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ABCB1—hematologic cancer	5.35e-06	5.28e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PTPN11—hematologic cancer	5.35e-06	5.28e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—FGF2—hematologic cancer	5.27e-06	5.21e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—SRC—hematologic cancer	5.23e-06	5.16e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—MAPK3—hematologic cancer	5.21e-06	5.14e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PIK3R1—hematologic cancer	5.2e-06	5.13e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GSTM1—hematologic cancer	5.2e-06	5.13e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—NCOR1—hematologic cancer	5.2e-06	5.13e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CREB1—hematologic cancer	5.18e-06	5.11e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—BRAF—hematologic cancer	5.11e-06	5.05e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—VEGFA—hematologic cancer	5.09e-06	5.02e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CCL2—hematologic cancer	5.07e-06	5e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—JAK2—hematologic cancer	5.06e-06	4.99e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IL6R—hematologic cancer	5.05e-06	4.99e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CREBBP—hematologic cancer	5.05e-06	4.98e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—STAT3—hematologic cancer	5.04e-06	4.97e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—NRAS—hematologic cancer	5.03e-06	4.96e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—PIK3CA—hematologic cancer	4.95e-06	4.89e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MDM2—hematologic cancer	4.94e-06	4.87e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	4.86e-06	4.8e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MAP2K1—hematologic cancer	4.82e-06	4.75e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MAPK3—hematologic cancer	4.81e-06	4.75e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MTOR—hematologic cancer	4.8e-06	4.74e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PIK3CB—hematologic cancer	4.8e-06	4.74e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GSTP1—hematologic cancer	4.79e-06	4.73e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PIK3CD—hematologic cancer	4.78e-06	4.72e-05	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—PIK3CA—hematologic cancer	4.74e-06	4.68e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—KRAS—hematologic cancer	4.68e-06	4.62e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MYC—hematologic cancer	4.68e-06	4.62e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TGFB1—hematologic cancer	4.67e-06	4.61e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	4.63e-06	4.57e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—MTHFR—hematologic cancer	4.59e-06	4.53e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—HRAS—hematologic cancer	4.58e-06	4.52e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—FGF2—hematologic cancer	4.58e-06	4.52e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ABCB1—hematologic cancer	4.53e-06	4.48e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PIK3R1—hematologic cancer	4.52e-06	4.46e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CDKN1B—hematologic cancer	4.51e-06	4.45e-05	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—AKT1—hematologic cancer	4.46e-06	4.4e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CASP3—hematologic cancer	4.42e-06	4.36e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IL2—hematologic cancer	4.41e-06	4.35e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GSTM1—hematologic cancer	4.4e-06	4.34e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—NCOR1—hematologic cancer	4.4e-06	4.34e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—JAK2—hematologic cancer	4.39e-06	4.33e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—IL6—hematologic cancer	4.39e-06	4.33e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—KRAS—hematologic cancer	4.33e-06	4.27e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—PIK3CA—hematologic cancer	4.3e-06	4.25e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CCND1—hematologic cancer	4.3e-06	4.24e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—JUN—hematologic cancer	4.29e-06	4.23e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MDM2—hematologic cancer	4.29e-06	4.23e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PIK3CB—hematologic cancer	4.17e-06	4.12e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MTOR—hematologic cancer	4.17e-06	4.12e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CDKN1A—hematologic cancer	4.16e-06	4.1e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PTEN—hematologic cancer	4.15e-06	4.1e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MAPK8—hematologic cancer	4.06e-06	4.01e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—AKT1—hematologic cancer	4.05e-06	4e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—HRAS—hematologic cancer	3.98e-06	3.93e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PIK3CA—hematologic cancer	3.97e-06	3.92e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—EP300—hematologic cancer	3.96e-06	3.91e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CDKN1B—hematologic cancer	3.91e-06	3.86e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—MTHFR—hematologic cancer	3.89e-06	3.84e-05	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—AKT1—hematologic cancer	3.87e-06	3.82e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PIK3CG—hematologic cancer	3.86e-06	3.81e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—SRC—hematologic cancer	3.85e-06	3.8e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TP53—hematologic cancer	3.85e-06	3.8e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CASP3—hematologic cancer	3.84e-06	3.79e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IL2—hematologic cancer	3.83e-06	3.78e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—IL6—hematologic cancer	3.81e-06	3.76e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—VEGFA—hematologic cancer	3.75e-06	3.7e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CCND1—hematologic cancer	3.73e-06	3.68e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—JUN—hematologic cancer	3.73e-06	3.68e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—STAT3—hematologic cancer	3.71e-06	3.66e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NRAS—hematologic cancer	3.7e-06	3.65e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—HRAS—hematologic cancer	3.68e-06	3.63e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CDKN1A—hematologic cancer	3.61e-06	3.56e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PTEN—hematologic cancer	3.6e-06	3.56e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CREBBP—hematologic cancer	3.58e-06	3.53e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MAPK3—hematologic cancer	3.55e-06	3.5e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MAPK8—hematologic cancer	3.52e-06	3.48e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IL6—hematologic cancer	3.52e-06	3.47e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—AKT1—hematologic cancer	3.52e-06	3.47e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MYC—hematologic cancer	3.45e-06	3.4e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TGFB1—hematologic cancer	3.44e-06	3.4e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—EP300—hematologic cancer	3.44e-06	3.39e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	3.43e-06	3.38e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PIK3CD—hematologic cancer	3.39e-06	3.35e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ALB—hematologic cancer	3.35e-06	3.3e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—SRC—hematologic cancer	3.34e-06	3.3e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PIK3CG—hematologic cancer	3.27e-06	3.23e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—VEGFA—hematologic cancer	3.25e-06	3.21e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—AKT1—hematologic cancer	3.25e-06	3.21e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—STAT3—hematologic cancer	3.22e-06	3.18e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NRAS—hematologic cancer	3.21e-06	3.17e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PIK3R1—hematologic cancer	3.2e-06	3.16e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—KRAS—hematologic cancer	3.19e-06	3.14e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MAPK3—hematologic cancer	3.08e-06	3.04e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CREBBP—hematologic cancer	3.03e-06	2.99e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MYC—hematologic cancer	2.99e-06	2.96e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TGFB1—hematologic cancer	2.99e-06	2.95e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PIK3CB—hematologic cancer	2.96e-06	2.92e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PIK3CA—hematologic cancer	2.93e-06	2.89e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PIK3CD—hematologic cancer	2.87e-06	2.84e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ALB—hematologic cancer	2.84e-06	2.8e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TP53—hematologic cancer	2.83e-06	2.8e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—KRAS—hematologic cancer	2.77e-06	2.73e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PIK3R1—hematologic cancer	2.71e-06	2.68e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—HRAS—hematologic cancer	2.71e-06	2.67e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IL6—hematologic cancer	2.59e-06	2.56e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PTEN—hematologic cancer	2.55e-06	2.52e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PIK3CA—hematologic cancer	2.54e-06	2.51e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PIK3CB—hematologic cancer	2.5e-06	2.47e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TP53—hematologic cancer	2.46e-06	2.43e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—EP300—hematologic cancer	2.44e-06	2.4e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—AKT1—hematologic cancer	2.39e-06	2.36e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—HRAS—hematologic cancer	2.35e-06	2.32e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IL6—hematologic cancer	2.25e-06	2.22e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PTEN—hematologic cancer	2.16e-06	2.14e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—AKT1—hematologic cancer	2.08e-06	2.05e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—EP300—hematologic cancer	2.06e-06	2.04e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PIK3CA—hematologic cancer	1.8e-06	1.78e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PIK3CA—hematologic cancer	1.53e-06	1.51e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—AKT1—hematologic cancer	1.47e-06	1.45e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—AKT1—hematologic cancer	1.25e-06	1.23e-05	CbGpPWpGaD
